Profile data is unavailable for this security.
About the company
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
- Revenue in USD (TTM)3.31m
- Net income in USD-14.05m
- Incorporated2018
- Employees8.00
- LocationMarker Therapeutics Inc4551 KENNEDY COMMERCE DR.HOUSTON 77032United StatesUSA
- Phone+1 (713) 400-6400
- Fax+1 (302) 655-5049
- Websitehttps://markertherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuo Therapeutics Inc | 608.53k | -3.17m | 35.35m | -- | -- | 34.02 | -- | 58.09 | -0.0754 | -0.0754 | 0.0145 | 0.0235 | 0.2471 | 0.5609 | 3.55 | -- | -128.78 | -116.16 | -173.76 | -354.84 | 79.28 | 70.02 | -521.17 | -854.53 | 2.01 | -1,002.61 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| Apollomics Inc | 0.00 | -677.48k | 35.49m | -- | -- | 0.0424 | -- | -- | -0.0505 | -0.0505 | 0.00 | 9.36 | 0.00 | -- | -- | -- | -0.6357 | -- | -0.6538 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -281.92 | -- | -- | -- |
| DURECT Corp | 8.55m | -27.62m | 36.00m | 58.00 | -- | 2.38 | -- | 4.21 | -1.12 | -1.12 | 0.3257 | 0.4873 | 0.1624 | 0.7927 | 3.65 | 147,379.30 | -52.47 | -37.34 | -124.79 | -53.44 | 79.91 | 91.83 | -323.16 | -139.11 | 1.20 | -55.63 | 0.5299 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Estrella Immunopharma Inc | 0.00 | -2.16m | 36.61m | -- | -- | 3.50 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 36.80m | 1.00 | -- | 0.2055 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Vyne Therapeutics Inc | 424.00k | -27.87m | 36.94m | 10.00 | -- | 0.4163 | -- | 87.12 | -6.84 | -7.00 | 0.0413 | 6.29 | 0.0061 | -- | 0.1639 | 42,400.00 | -40.27 | -108.41 | -45.86 | -138.57 | -- | -- | -6,573.82 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -13.21m | 37.16m | 6.00 | -- | 9.86 | -- | -- | -1.22 | -1.22 | 0.00 | 0.1987 | 0.00 | -- | -- | 0.00 | -128.63 | -144.28 | -552.70 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.24m | -42.19m | 37.18m | 57.00 | -- | 0.6489 | -- | 16.61 | -7.18 | -7.18 | 0.4056 | 6.21 | 0.0332 | -- | 0.8059 | 39,280.53 | -62.58 | -- | -77.39 | -- | -- | -- | -1,884.50 | -- | -- | -- | 0.0743 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 33.88m | -26.96m | 37.46m | 176.00 | -- | 1.55 | -- | 1.11 | -2.02 | -2.02 | 2.54 | 1.81 | 0.3951 | 1.26 | 3.01 | 192,494.30 | -30.57 | -34.75 | -45.42 | -46.91 | 59.19 | 55.98 | -77.37 | -153.72 | 2.60 | -- | 0.4388 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Marker Therapeutics Inc | 3.31m | -14.05m | 37.61m | 8.00 | -- | 2.67 | -- | 11.36 | -1.59 | -0.933 | 0.3753 | 1.58 | 0.1285 | -- | 1.93 | 413,892.50 | -54.49 | -53.74 | -69.03 | -62.25 | -- | -- | -424.20 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Incannex Healthcare Inc | 163.39k | -13.70m | 37.94m | -- | -- | 2.01 | -- | 232.18 | -0.3806 | -0.3806 | 0.0003 | 1.19 | 0.0038 | -- | 0.0554 | -- | -31.42 | -54.94 | -32.90 | -59.47 | -- | -- | -8,386.19 | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Natural Alternatives International, Inc. | 127.76m | -4.11m | 38.36m | 317.00 | -- | 0.4489 | 85.24 | 0.3002 | -0.705 | -0.705 | 21.87 | 14.03 | 0.8624 | 4.23 | 12.32 | 403,041.00 | -2.77 | 4.90 | -3.11 | 5.93 | 7.90 | 15.98 | -3.22 | 3.80 | 2.59 | -2.54 | 0.0988 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Unicycive Therapeutics Inc | 675.00k | -31.41m | 38.93m | 14.00 | -- | -- | -- | 57.67 | -1.62 | -1.62 | 0.0276 | -0.1096 | 0.0794 | -- | -- | 48,214.29 | -359.15 | -218.20 | -- | -609.54 | -- | -- | -4,525.04 | -3,877.49 | -- | -- | -- | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| ImmuCell Corp | 17.47m | -5.77m | 39.36m | 79.00 | -- | 1.56 | -- | 2.25 | -0.7454 | -0.7454 | 2.26 | 3.22 | 0.3941 | 1.96 | 8.86 | 221,160.40 | -13.03 | -5.16 | -14.19 | -5.53 | 22.15 | 40.04 | -33.05 | -12.64 | 0.8715 | -15.17 | 0.3238 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
Data as of May 03 2024. Currency figures normalised to Marker Therapeutics Inc's reporting currency: US Dollar USD
9.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aisling Capital Management LPas of 31 Dec 2023 | 314.29k | 3.53% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 222.55k | 2.50% |
| AR Asset Management, Inc.as of 31 Dec 2023 | 70.70k | 0.79% |
| Wedbush Securities, Inc. (Investment Management)as of 31 Dec 2023 | 69.50k | 0.78% |
| Geode Capital Management LLCas of 31 Dec 2023 | 60.05k | 0.67% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 37.55k | 0.42% |
| NFS Netfonds Financial Service GmbHas of 30 Sep 2023 | 25.44k | 0.29% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 24.80k | 0.28% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 20.28k | 0.23% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 19.75k | 0.22% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
